Sangamo Therapeutics, Inc.

Contributing Author

Recent Articles by Sangamo Therapeutics, Inc.

7 hours	Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease SGMO +7.71% GlobeNewswire
Feb-03	Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026 SGMO -31.33% SGMO -7.64% GlobeNewswire
Feb-03	Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering SGMO -31.33% GlobeNewswire
Dec-18	Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease SGMO GlobeNewswire
Dec-02	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy SGMO GlobeNewswire
Nov-21	Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease SGMO +9.97% GlobeNewswire
Nov-06	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results SGMO -16.29% GlobeNewswire
Oct-30	Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call SGMO GlobeNewswire
Sep-04	Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 SGMO GlobeNewswire
Aug-07	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results SGMO -8.93% SGMO -5.33% GlobeNewswire
Jul-31	Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call SGMO GlobeNewswire